Candida auris infections in China

Virulence. 2022 Dec;13(1):589-591. doi: 10.1080/21505594.2022.2054120.

Authors

Han Du¹, Jian Bing¹, Clarissa J Nobile^{2

3}, Guanghua Huang¹

Affiliations

¹ Shanghai Institute of Infectious Disease and Biosecurity, Department of Infectious Diseases, Huashan Hospital and State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
² Department of Molecular and Cell Biology, University of California, Merced, CA, USA.
³ Health Sciences Research Institute, University of California, Merced, CA, USA.

No abstract available

Keywords: Candida auris; China; emerging fungal pathogen; multidrug-resistance.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Antifungal Agents / pharmacology
Antifungal Agents / therapeutic use
Candida auris*
Candidiasis, Invasive*
China / epidemiology
Humans
Microbial Sensitivity Tests

Substances

Antifungal Agents

Supplementary concepts

Candida auris infection

Grants and funding

R35 GM124594/GM/NIGMS NIH HHS/United States